Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.

[1]  J. Skupień,et al.  Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. , 2017, Kidney international.

[2]  J. Skupień,et al.  Patterns of Estimated Glomerular Filtration Rate Decline Leading to End-Stage Renal Disease in Type 1 Diabetes , 2016, Diabetes Care.

[3]  N. Speybroeck,et al.  Classification and regression tree analysis vs. multivariable linear and logistic regression methods as statistical tools for studying haemophilia , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  A. Galecki,et al.  Improved glycemic control and risk of ESRD in patients with type 1 diabetes and proteinuria. , 2014, Journal of the American Society of Nephrology : JASN.

[5]  A. Cheung,et al.  GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  W. Knowler,et al.  Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes , 2014, Kidney international.

[7]  A. Galecki,et al.  Synergism Between Circulating Tumor Necrosis Factor Receptor 2 and HbA1c in Determining Renal Decline During 5–18 Years of Follow-up in Patients With Type 1 Diabetes and Proteinuria , 2014, Diabetes Care.

[8]  Merlin C. Thomas,et al.  Added Value of Soluble Tumor Necrosis Factor-α Receptor 1 as a Biomarker of ESRD Risk in Patients With Type 1 Diabetes , 2014, Diabetes Care.

[9]  V. Rigalleau,et al.  Association of Serum Concentration of TNFR1 With All-Cause Mortality in Patients With Type 2 Diabetes and Chronic Kidney Disease: Follow-up of the SURDIAGENE Cohort , 2014, Diabetes Care.

[10]  J. McMurray,et al.  Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. , 2013, The New England journal of medicine.

[11]  J. Skupień,et al.  Early Progressive Renal Decline Precedes the Onset of Microalbuminuria and Its Progression to Macroalbuminuria , 2013, Diabetes Care.

[12]  C. Elley,et al.  Derivation and Validation of a Renal Risk Score for People With Type 2 Diabetes , 2013, Diabetes Care.

[13]  K. Hunt,et al.  Baseline Markers of Inflammation Are Associated With Progression to Macroalbuminuria in Type 1 Diabetic Subjects , 2013, Diabetes Care.

[14]  Nish Chaturvedi,et al.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[15]  M. Woodward,et al.  Prediction of kidney-related outcomes in patients with type 2 diabetes. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  J. Skupień,et al.  The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end stage renal disease , 2012, Kidney international.

[17]  T. Mayadas,et al.  Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[18]  T. Mayadas,et al.  Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[19]  J. Chan,et al.  Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study , 2011, Diabetologia.

[20]  Patrick J Heagerty,et al.  Temporal trends in the prevalence of diabetic kidney disease in the United States. , 2011, JAMA.

[21]  M. Donohue,et al.  Pirfenidone for diabetic nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[22]  N. Tangri,et al.  A predictive model for progression of chronic kidney disease to kidney failure. , 2011, JAMA.

[23]  J. Skupień,et al.  Risk for ESRD in type 1 diabetes remains high despite renoprotection. , 2011, Journal of the American Society of Nephrology : JASN.

[24]  Merlin C. Thomas,et al.  Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. , 2011, Journal of the American Society of Nephrology : JASN.

[25]  M. Woodward,et al.  Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. , 2010, European heart journal.

[26]  D. Churchill,et al.  Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. , 2010, JAMA.

[27]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[28]  Andrzej S Krolewski,et al.  Genetics of Kidneys in Diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes. , 2006, Journal of the American Society of Nephrology : JASN.

[29]  F. Facchini,et al.  A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. , 2003, Diabetes.

[30]  Charles Maynard,et al.  A primer and comparative review of major US mortality databases. , 2002, Annals of epidemiology.

[31]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[32]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[33]  G. Gearin,et al.  Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. , 1996, Journal of the American Society of Nephrology : JASN.

[34]  A. Krolewski,et al.  Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. , 1995, The New England journal of medicine.

[35]  T. Pajak,et al.  Analysis of the probability and risk of cause-specific failure. , 1994, International journal of radiation oncology, biology, physics.

[36]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[37]  R. Olshen,et al.  Points of Significance: Classification and regression trees , 2017, Nature Methods.

[38]  J. Navarro-González,et al.  Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. , 2015, Journal of the American Society of Nephrology : JASN.

[39]  Kathleen F. Kerr,et al.  Net reclassification indices for evaluating risk prediction instruments: a critical review. , 2014, Epidemiology.

[40]  S. Griffen,et al.  Increased Toll-like Receptor (tlr) 2 and Tlr4 Expression in Monocytes from Patients with Type 1 Diabetes: Further , 2022 .

[41]  Rury R Holman,et al.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.

[42]  P. Eggers,et al.  Renal replacement therapy in the United States: data from the United States Renal Data System. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  A Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.